4/18/2023 | PV | BioCryst gets $450 million in commitments from Pharmakon Advisors
|
11/22/2021 | PV | BioCryst amends credit agreement to make room for royalty payments
|
2/6/2019 | HYIG | Market Commentary: BioCryst gets $100 million loan; Coca-Cola Consolidated eyes $100 million notes due 2026
|
2/6/2019 | PV | New Issue: BioCryst negotiates $100 million secured loan with MidCap Financial
|
8/5/2013 | PP | BioCryst greenshoe exercised for $20.24 million public stock offering
|
8/1/2013 | PP | BioCryst prices $17.6 million public offering of common stock at $4.40
|
7/30/2013 | PP | BioCryst Pharmaceuticals to price $20 million public offering of stock
|
7/1/2011 | PP | BioCryst inks at-market issuance sales agreement for up to $70 million
|
6/28/2011 | CVPF | BioCryst Pharmaceuticals files $70 million stock and preferreds shelf
|
3/9/2011 | PV | New Issue: BioCryst subsidiary places $30 million of 14% notes due 2020
|
6/2/2009 | SS | BioCryst Pharmaceuticals investors sell shares, reduce stake to 17.9%
|
12/1/2008 | CV | BioCryst Pharmaceuticals files $70 million shelf
|
8/7/2007 | PP | Market Commentary: NPS Pharmaceuticals pockets $50 million; Azur wraps $48 million stock deal
|
8/6/2007 | PP | New Issue: BioCryst Pharmaceuticals secures $65.3 million from stock sale
|
8/6/2007 | PP | Market Commentary: BioCryst secures $65.3 million from stock sale; Curis to close $13 million offering
|
11/8/2006 | BT | BioCryst third-quarter net loss doubles to $15.6 million
|
10/3/2006 | BT | Market Commentary: Acorda shoots up 32%; Isis lower after analyst day; Gilead off 3.5%, Myogen eases; Amgen better
|
9/27/2006 | BT | Market Commentary: Nabi hires BofA, up after hours; Millennium off; BioSante dives 14.5%; BioCryst, Novavax gain
|
9/7/2006 | BT | BioCryst preparing to start pivotal trial of anticancer compound Fodosine
|
9/1/2006 | BT | Market Commentary: Sanofi flu news pushes smaller biotechs lower; BioDelivery off 10%; Curis slips on R&D shift
|
8/28/2006 | BT | Market Commentary: Discovery Partners up 9% on MedImmune, Infinity pact; EPIX plunges; Sinovac soars; PDL up
|
8/7/2006 | BT | BioCryst receives FDA approval for phase 2b trial of anticancer compound Fodosine
|
7/27/2006 | BT | Market Commentary: Adams hit 4%; Conor slips after follow-on; Diomed pockets $10 million from PIPE; Oscient gains
|
7/26/2006 | BT | Market Commentary: DOV comes off highs; Neurocrine extends losses after hours; bird flu stocks fly; NicOx rises
|
6/14/2006 | BT | BioCryst, Green Cross to develop influenza neuraminidase inhibitor in Korea
|
6/8/2006 | BT | Market Commentary: AtheroGenics drops; Nastech up; Novavax, BioCryst decline; Sirna slides; Acadia off; XenoPort drops
|
5/24/2006 | BT | Market Commentary: Sirna, Minrad, AngioDynamics follow-on deals get off; bird flu vaccine names continue to climb
|
5/23/2006 | BT | Market Commentary: Sirna slides 8% ahead of reduced deal; Auxilium gains; Alnylam off; bird flu names up after hours
|
4/6/2006 | BT | BioCryst says forodesine HCL can cause cell death in certain cancers
|
3/16/2006 | BT | Market Commentary: Novavax, Nastech flu names on a tear; BioMarin higher on trial; Elite bobs, Titan slips on PIPEs
|
3/9/2006 | BT | BioCryst begins intravenous peramivir phase 1 trial as possible avian flu vaccine
|
2/28/2006 | BT | Market Commentary: Generex recoils along with most flu names; King Pharma clubbed; Elan, Biogen hit by analyst poll
|
2/27/2006 | BT | Market Commentary: Novavax bags $20 million, up 12%; BioCryst, Generex, Gilead also take flight; Cerus deal emerges
|
2/2/2006 | BT | BioCryst signs Fodosine license agreement with Mundipharma
|
1/17/2006 | BT | BioCryst gets fast track approval from FDA for flu drug
|
12/22/2005 | BT | Market Commentary: AtheroGenics zooms on $1 billion pact with AstraZeneca; Regeneron rises 6%; BioCryst bounces 16%
|
12/22/2005 | BT | Market Commentary: AtheroGenics zooms on $1 billion pact with AstraZeneca; Regeneron rises 6%; BioCryst bounces 16%
|
12/22/2005 | BT | BioCryst begins phase 1/2 trial for Fodosine in patients with leukemia
|
12/22/2005 | BT | BioCryst gets FDA OK to begin intravenous studies on flu inhibitor peramivir
|
12/16/2005 | PP | Market Commentary: Semitool to complete $29.55 million direct deal; Avanir details $20.1 million direct placement of stock
|
12/15/2005 | PP | Market Commentary: BioCryst set to close $30 million direct offering; 8x8's shares fall on word of $15 million stock deal
|
12/15/2005 | BTPP | New Issue: BioCryst in deal for $30 million direct placement of shares
|
12/15/2005 | BT | Market Commentary: OSI Pharma on deck; Oxigene off on steep discount; BioCryst slips on PIPE; Somaxon sinks on debut
|
12/12/2005 | BT | BioCryst says research shows promising results for Fodosine in leukemia
|
11/30/2005 | BT | Roche gets BioCryst license to help develop, commercialize BCX-4208
|
11/30/2005 | BT | Market Commentary: Adams secondary launched; Isis off; Durect up; Inspire, BioCryst rocket up; Merck bonds weaker
|
11/28/2005 | BT | Market Commentary: Merck pressures biotech sector; Amgen, Genentech lead slide; Enzon, BioCryst, Pozen up a tad
|
11/28/2005 | BT | BioCryst submits application for injectable peramivir, a flu vaccine that may even work against avian flu
|
11/16/2005 | BT | Market Commentary: Gilead gains on Roche settlement; AtheroGenics sinks; Amylin rises
|
10/17/2005 | BT | BioCryst asks FDA to approve design of trial for Fodosine
|
10/12/2005 | BT | Market Commentary: Vical falls 20% on PIPEs deal; Threshold, Dynavax off on stock sales; Pharma Product higher
|
10/10/2005 | BT | Market Commentary: Holiday makes for thin market; Gilead, niche flu drug names go higher; Human Genome lower yet
|
9/2/2005 | BT | BioCryst Pharmaceuticals files $85 million shelf
|
2/17/2005 | PP | New Issue: BioCryst plans $24 million direct placement of stock
|
2/17/2005 | PP | Market Commentary: Private placement volume remains weak; Liquor Stores Income Fund to raise C$30 million
|